Login to Your Account



Clinic Roundup


Wednesday, April 4, 2012
• Human Genome Sciences Inc., of Rockville, Md., said partner GlaxoSmithKline plc, of London, announced top-line results from seven of eight Phase III (Harmony) trials of albiglutide for Type II diabetes showing positive results. Harmony 6 compared albiglutide to preprandial insulin, finding clinically significant reductions in HbA1c. Harmony 7 results, comparing albiglutide to once-a-day liraglutide, were announced in November 2011. For ongoing Harmony 1 through 5 trials, early study data showed results consistent with the two completed studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription